A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis

This is a multicenter, double-blinded, double-dummy, active-controlled, randomized, Phase III clinical trial to evaluate the efficacy and safety of DA-6034 and to demonstrate the non-inferiority of DA-6034 compared with Rebamipide in patients with acute or chronic gastritis. Subjects will receive 45mg, 90mg of DA-6034 and 300mg of Rebamipide, two tablets, three times a day for two weeks.

Inclusion Criteria:

• Diagnosed with acute gastritis or chronic gastritis
• 1 or more erosions found in the gastroscope examination
• Age should be: 20≤age≤75

Exclusion Criteria:

• A patient with peptic ulcer and a gastroesophageal reflux disease.
• Received a medication including non-steroid anti-inflammatory drug 2 weeks before the initiation
• Had a surgery regarding gastroesophageal
• A patient with Zollinger-Ellison syndrome
• Had a medical history of a malignant tumor
• A patient who is currently taking anti-thrombotic drugs